What podcasts say about Mike Doustdar
Every statement, with the speaker, the exact quote and the moment it was said.
What Mike Doustdar has said on podcasts
17 statements · 15 positive · 1 negative · 1 neutral
Novo Nordisk’s pill launch is the best pharmaceutical product launch ever.
“this makes this launch the best product launch in the history of pharmaceuticals.”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 12:48
Novo Nordisk improved guidance and exceeded consensus expectations.
“we improved guidance, actually, and beat the consensus quite a bit.”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 13:24
Novo Nordisk substantially reduced Ozempic and Wegovy prices.
“we reduced the prices of Ozempic and Vigovie tremendously.”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 14:03
Eli Lilly has been gaining GLP-1 market share from Novo Nordisk.
“Lilly has been gaining market share.”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 15:01
Novo Nordisk’s pill reduced weight 17% versus Eli Lilly’s pill at 12% in separate trials.
“We have introduced the pill. that reduces your weight by 17%. Lily's Pill reduces your weight by 12%”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 17:49
Novo Nordisk's weight-loss pill is receiving 50,000 weekly prescriptions.
“we have now, on a weekly basis, 50,000 prescriptions coming in”
Open the episode · Mad Money w/ Jim Cramer 2/4/26Listen at 11:37
Novo Nordisk's pill reached 170,000 American users within four weeks.
“that actually translates to 170,000 Americans are on the pill in four weeks' time”
Open the episode · Mad Money w/ Jim Cramer 2/4/26Listen at 11:44
Novo Nordisk's 7.2-milligram semaglutide matched tirzepatide's weight-loss efficacy in a trial.
“We have done a trial called Step Up with semaglutide at 7.2 milligram that shows actually weight loss efficacy on par with trisepatide.”
Open the episode · Mad Money w/ Jim Cramer 2/4/26Listen at 13:57
Semaglutide provides cardiovascular, liver, and kidney protection.
“semaglutide gives you cardio protection, liver protection, kidney protection”
Open the episode · Mad Money w/ Jim Cramer 2/4/26Listen at 14:27
Novo Nordisk expects lower prices to drive future volume growth and improve results.
“Better days are ahead of us because volume uptake will come on the back of lower prices.”
Open the episode · Mad Money w/ Jim Cramer 2/4/26Listen at 17:39
Novo Nordisk believes it can supply its weight-loss pill adequately.
“We feel very confident from a supply point of view”
Open the episode · Mad Money w/ Jim Cramer 2/4/26Listen at 18:25
Novo Nordisk and its competitor have roughly 10–15 million GLP-1 users.
“we have around 10, 15 million people right now on GLP-1 together with our competitor.”
Open the episode · Mad Money w/ Jim Cramer 1/12/26Listen at 5:54
Novo Nordisk’s oral GLP-1 pill can expand the obesity-treatment market.
“the pill is able to expand the market.”
Open the episode · Mad Money w/ Jim Cramer 1/12/26Listen at 6:26
Novo Nordisk’s Wegovy pill reduces weight by 16.6%, matching the injectable version.
“it's not only reducing your weight, actually at the same level, 16.6% as the injectable version of Vigovi”
Open the episode · Mad Money w/ Jim Cramer 1/12/26Listen at 9:08
Compounded GLP-1 products are knockoffs and should be illegal.
“They're knockoff products. So this should be completely illegal.”
Open the episode · Mad Money w/ Jim Cramer 1/12/26Listen at 10:57
Wegovy’s pill and injection reduce weight equally by 16.6%.
“both of which reduce your weight by 16.6%. So you don't need to compromise anymore.”
Open the episode · Mad Money w/ Jim Cramer 1/12/26Listen at 12:38
Novo Nordisk’s hemophilia treatment stopped 98% of tested bleedings in trials.
“98% of the bleedings. that were tested in the clinical trials were basically stopped.”
Open the episode · Mad Money w/ Jim Cramer 1/12/26Listen at 15:38
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.